

Cancer Immunology, Infectious Diseases

## **CD169 defines activated CD14<sup>+</sup> monocytes with enhanced CD8<sup>+</sup> T cell activation capacity**

*<sup>1</sup>Affandi AJ, <sup>1</sup>Olesek K, <sup>2</sup>Saris A, <sup>1,3</sup>Zwart ES, <sup>4</sup>Nossent EJ, <sup>5</sup>de Gruijl TD, <sup>1</sup>Garcia Vallejo JJ, <sup>1</sup>van Kooyk Y, <sup>1</sup>den Haan JMM*

<sup>1</sup>Dept. of Molecular Cell Biology and Immunology, <sup>2</sup>Center for Experimental and Molecular Medicine, <sup>3</sup>Dept. of Surgery, <sup>4</sup>Department of Pulmonary Medicine, <sup>5</sup>Department of Medical Oncology

Monocytes are antigen-presenting cells (APCs) that play diverse roles in promoting or regulating inflammatory responses, but their role in T cell stimulation is not well defined. In inflammatory conditions, monocytes frequently show increased expression of CD169/Siglec-1, a type-I interferon (IFN-I)-regulated protein. However, little is known about the phenotype and function of these CD169<sup>+</sup> monocytes. Here, we investigated the phenotype of human CD169<sup>+</sup> monocytes in different diseases, their capacity to activate CD8<sup>+</sup> T cells, and the potential for a targeted-vaccination approach. Using spectral flow cytometry, we detected CD169 expression by CD14<sup>+</sup> CD16<sup>-</sup> classical and CD14<sup>+</sup> CD16<sup>+</sup> intermediate monocytes, and unbiased high-dimensional analysis showed that they were distinct from dendritic cells, including the recently described CD14-expressing DC3. CD169<sup>+</sup> monocytes expressed higher expression of co-stimulatory- and HLA-molecules, suggesting an increased activation state. IFN $\alpha$  treatment highly upregulated CD169 expression on CD14<sup>+</sup> monocytes and boosted their capacity to cross-present antigen to CD8<sup>+</sup> T cells. Furthermore, scRNA-seq and flow cytometry analyses showed that CD169<sup>+</sup> monocytes were present in the blood and bronchoalveolar lavage fluid of COVID-19 patients, and in the blood of patients with five different types of cancers. Finally, we evaluated two CD169-targeting nanovaccine platforms, antibody- or liposome-based, and we showed that CD169<sup>+</sup> monocytes efficiently presented tumor-associated peptides gp100 and WT1 to antigen-specific CD8<sup>+</sup> T cells. In conclusion, our data indicate that CD169<sup>+</sup> monocytes are activated monocytes with enhanced CD8<sup>+</sup> T cell stimulatory capacity and that they emerge as an interesting target in nanovaccine strategies, because of their presence in health and different diseases.